Carole Farrell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Carole Farrell has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alex Molassiotis
College of Arts, Humanities and Education, University of Derby, Derby, United Kingdom
4 shared publications - Aishwarya Bandla
National University Health System
1 shared publication - Alexandre Chan
School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA
1 shared publication - Anthony Kwun To Leung
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR
1 shared publication Bethan Daniel
1 shared publication- Catherine Heaven
The Christie NHS Trust, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK
1 shared publication
Latest Publications
- Open Access
- 8 February 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-19
Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
There are inconsistencies in the literature regarding the prevalence and assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored CIPN natural history and its characteristics in patients receiving taxane- and platinum-based chemotherapy. Multi-country multisite prospective longitudinal observational study. Patients were assessed before commencing and three weekly during chemotherapy for up to six cycles, and at 6,9, and 12 months using clinician-based scales (NCI-CTCAE; WHO-CIPN criterion), objective assessments (cotton wool test;10 g monofilament); patient-reported outcome measures (FACT/GOG-Ntx; EORTC-CIPN20), and Nerve Conduction Studies. In total, 343 patients were recruited in the cohort, providing 2399 observations. There was wide variation in CIPN prevalence rates using different assessments (14.2–53.4%). Prevalence of sensory neuropathy (and associated symptom profile) was also different in each type of chemotherapy, with paclitaxel (up to 63%) and oxaliplatin (up to 71.4%) showing the highest CIPN rates in most assessments and a more complex symptom profile. Peak prevalence was around the 6-month assessment (up to 71.4%). Motor neurotoxicity was common, particularly in the docetaxel subgroup (up to 22.1%; detected by NCI-CTCAE). There were relatively moderately-to-low correlations between scales (rs = 0.15,p < 0.05-rs = 0.48 p < 0.001), suggesting that they measure different neurotoxicity aspects from each other. Cumulative chemotherapy dose was not associated with onset and course of CIPN. The historical variation reported in CIPN incidence and prevalence is possibly confounded by disagreement between assessment modalities. Clinical practice should consider assessment of motor neuropathy for neurotoxic chemotherapy. Current scales may not be all appropriate to measure CIPN in a valid way, and a combination of scales are needed.
- 8 February 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-19
Open AccessAre we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
There are inconsistencies in the literature regarding the prevalence and assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored CIPN natural history and its characteristics in patients receiving taxane- and platinum-based chemotherapy. Multi-country multisite prospective longitudinal observational study. Patients were assessed before commencing and three weekly during chemotherapy for up to six cycles, and at 6,9, and 12 months using clinician-based scales (NCI-CTCAE; WHO-CIPN criterion), objective assessments (cotton wool test;10 g monofilament); patient-reported outcome measures (FACT/GOG-Ntx; EORTC-CIPN20), and Nerve Conduction Studies. In total, 343 patients were recruited in the cohort, providing 2399 observations. There was wide variation in CIPN prevalence rates using different assessments (14.2–53.4%). Prevalence of sensory neuropathy (and associated symptom profile) was also different in each type of chemotherapy, with paclitaxel (up to 63%) and oxaliplatin (up to 71.4%) showing the highest CIPN rates in most assessments and a more complex symptom profile. Peak prevalence was around the 6-month assessment (up to 71.4%). Motor neurotoxicity was common, particularly in the docetaxel subgroup (up to 22.1%; detected by NCI-CTCAE). There were relatively moderately-to-low correlations between scales (rs = 0.15,p < 0.05-rs = 0.48 p < 0.001), suggesting that they measure different neurotoxicity aspects from each other. Cumulative chemotherapy dose was not associated with onset and course of CIPN. The historical variation reported in CIPN incidence and prevalence is possibly confounded by disagreement between assessment modalities. Clinical practice should consider assessment of motor neuropathy for neurotoxic chemotherapy. Current scales may not be all appropriate to measure CIPN in a valid way, and a combination of scales are needed.
- 28 August 2018
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 36, 82-88
Understanding the impact of chemotherapy on dignity for older people and their partners
- 28 August 2018
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 36, 82-88
Understanding the impact of chemotherapy on dignity for older people and their partners
- 8 March 2018
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 17 (2) , 25-33
Oral vinorelbine: a narrative review
The incidence of many cancers is increasing; coupled with a decline in mortality rates (Cancer Research UK 2017a) this translates to more people living with and beyond their cancer diagnosis. Cancer is generally viewed as a chronic condition and this is often true for many diagnosed with metastatic breast cancer (MBC). In advanced/metastatic disease, there is a greater emphasis on promoting patients’ quality of life, and oral treatments can have additional benefits for patients, such as ease of administration, potentially reduced toxicities and fewer hospital visits. Oral vinorelbine was licenced in 2006 for the treatment of non-small cell lung cancer and MBC. This paper provides a narrative review of evidence from clinical trials, outlining the development and clinical application of oral vinorelbine, including implications for clinical practice and patient care.
- 8 March 2018
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 17 (2) , 25-33
Oral vinorelbine: a narrative review
The incidence of many cancers is increasing; coupled with a decline in mortality rates (Cancer Research UK 2017a) this translates to more people living with and beyond their cancer diagnosis. Cancer is generally viewed as a chronic condition and this is often true for many diagnosed with metastatic breast cancer (MBC). In advanced/metastatic disease, there is a greater emphasis on promoting patients’ quality of life, and oral treatments can have additional benefits for patients, such as ease of administration, potentially reduced toxicities and fewer hospital visits. Oral vinorelbine was licenced in 2006 for the treatment of non-small cell lung cancer and MBC. This paper provides a narrative review of evidence from clinical trials, outlining the development and clinical application of oral vinorelbine, including implications for clinical practice and patient care.
- 10 October 2017
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 16 (8) , 26-33
Evaluating health and well-being interventions for patients with secondary breast cancer
- 10 October 2017
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 16 (8) , 26-33
Evaluating health and well-being interventions for patients with secondary breast cancer
- 11 April 2017
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 16 (3) , 32-38
Peripheral cannulae in oncology: nurses’ confidence and patients’ experiences
The insertion and care of peripheral intravenous cannulae (PIVCs) is a role performed by clinical staff that is fundamental to oncology. Previous research indicates nurses’ confidence and experience could mediate successful first attempt insertion, increasing the longevity of PIVCs and improving the patient experience. The aim of this audit was to provide a snapshot of care and maintenance of PIVCs, patients’ experiences and nurses’ confidence at a specialist cancer hospital. An audit tool assessing PIVC care practices (n=51) and a patient experience questionnaire (n=65) were completed. A questionnaire assessing nurses’ confidence and training needs was completed by 36 nurses. The findings raise some concerns about clinical practice when inserting PIVCs and ongoing care, with 80% adherence to cannulation policies. Almost half of insertion procedures failed at the first attempt and 17% of nurses lacked confidence in PIVC insertion and in recognising or responding to common complications. Patient satisfaction was high for ongoing PIVC care (95%), although some reported increased pain and anxiety after PIVC insertion, with some unresolved concerns. The audit highlights several important areas for improvement in relation to PIVC insertion and maintenance and the need for greater adherence to clinical guidelines/policy and additional training were identified.
- 11 April 2017
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 16 (3) , 32-38
Peripheral cannulae in oncology: nurses’ confidence and patients’ experiences
The insertion and care of peripheral intravenous cannulae (PIVCs) is a role performed by clinical staff that is fundamental to oncology. Previous research indicates nurses’ confidence and experience could mediate successful first attempt insertion, increasing the longevity of PIVCs and improving the patient experience. The aim of this audit was to provide a snapshot of care and maintenance of PIVCs, patients’ experiences and nurses’ confidence at a specialist cancer hospital. An audit tool assessing PIVC care practices (n=51) and a patient experience questionnaire (n=65) were completed. A questionnaire assessing nurses’ confidence and training needs was completed by 36 nurses. The findings raise some concerns about clinical practice when inserting PIVCs and ongoing care, with 80% adherence to cannulation policies. Almost half of insertion procedures failed at the first attempt and 17% of nurses lacked confidence in PIVC insertion and in recognising or responding to common complications. Patient satisfaction was high for ongoing PIVC care (95%), although some reported increased pain and anxiety after PIVC insertion, with some unresolved concerns. The audit highlights several important areas for improvement in relation to PIVC insertion and maintenance and the need for greater adherence to clinical guidelines/policy and additional training were identified.
- 1 April 2017
- Published by Elsevier in International Journal of Nursing Studies
- Vol. 69, 1-8
Are nurse-led chemotherapy clinics really nurse-led? An ethnographic study
- 1 April 2017
- Published by Elsevier in International Journal of Nursing Studies
- Vol. 69, 1-8
Are nurse-led chemotherapy clinics really nurse-led? An ethnographic study
- 10 November 2015
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 14 (9) , 14-19
Role of specialist liaison nurses in caring for young adults
As the needs of teenagers and young adults (TYAs) with cancer are complex and different to those of children and adults it is crucial to have age-appropriate specialist care. Although there have been tremendous developments in this area by organisations such as the Teenage Cancer Trust, CLIC Sargent and Macmillan, further improvements are needed in care transitions and pathways. The success of local and national service innovations stems from the involvement of TYAs working in partnership with health professionals to ensure that care is age appropriate and their needs are met. Specialist liaison nurses are valuable in providing continuity of care across health settings at all stages of cancer, including end of life. This article provides insight into clinical services for TYAs with cancer, focusing on the role of specialist liaison nurses, and discusses the implications for patients, their families and health professionals.
- 10 November 2015
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 14 (9) , 14-19
Role of specialist liaison nurses in caring for young adults
As the needs of teenagers and young adults (TYAs) with cancer are complex and different to those of children and adults it is crucial to have age-appropriate specialist care. Although there have been tremendous developments in this area by organisations such as the Teenage Cancer Trust, CLIC Sargent and Macmillan, further improvements are needed in care transitions and pathways. The success of local and national service innovations stems from the involvement of TYAs working in partnership with health professionals to ensure that care is age appropriate and their needs are met. Specialist liaison nurses are valuable in providing continuity of care across health settings at all stages of cancer, including end of life. This article provides insight into clinical services for TYAs with cancer, focusing on the role of specialist liaison nurses, and discusses the implications for patients, their families and health professionals.
- 25 February 2015
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 24 (Sup4) , S4-S12
Legitimising fatigue after breast-cancer treatment
This study aimed to explore the experience of women living with fatigue following chemotherapy for breast cancer. Six focus groups were conducted (n=40); all participants had taken part in a multi-site acupuncture trial. There were three to seven people per focus group. Additionally, two people attended one-to-one interviews and four people provided written responses to the trigger questions. The audiotapes from these sessions were transcribed and analysed using a thematic approach. Participants raised concerns about fatigue possibly being a symptom of the cancer coming back or a sign of senility. Respondents described the effects of fatigue on relationships, sexuality, social life, home life and returning to work. The Coping with Fatigue booklet ( Macmillan Cancer Support, 2011 ) was discussed in terms of legitimising the experience of cancer-related fatigue and explaining symptoms to family and work colleagues. More research work is required to evaluate non-pharmaceutical interventions and advice to support women living with fatigue after chemotherapy for breast cancer.
- 25 February 2015
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 24 (Sup4) , S4-S12
Legitimising fatigue after breast-cancer treatment
This study aimed to explore the experience of women living with fatigue following chemotherapy for breast cancer. Six focus groups were conducted (n=40); all participants had taken part in a multi-site acupuncture trial. There were three to seven people per focus group. Additionally, two people attended one-to-one interviews and four people provided written responses to the trigger questions. The audiotapes from these sessions were transcribed and analysed using a thematic approach. Participants raised concerns about fatigue possibly being a symptom of the cancer coming back or a sign of senility. Respondents described the effects of fatigue on relationships, sexuality, social life, home life and returning to work. The Coping with Fatigue booklet ( Macmillan Cancer Support, 2011 ) was discussed in terms of legitimising the experience of cancer-related fatigue and explaining symptoms to family and work colleagues. More research work is required to evaluate non-pharmaceutical interventions and advice to support women living with fatigue after chemotherapy for breast cancer.
- 1 April 2011
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 15 (2) , 160-166
Exploring the scope of oncology specialist nurses’ practice in the UK
- 1 April 2011
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 15 (2) , 160-166
Exploring the scope of oncology specialist nurses’ practice in the UK